Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris Parker, Dominic Hague, Raj Persad et al.|The Lancet|2024Cited by 50
A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISEHeather Payne, Marco De Santis, Angus Robinson et al.|European Urology Open Science|2020Cited by 1
Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISEDavid Mott, Marco Pavesi, Michael Herdman et al.|European Urology Open Science|2020Cited by 0